Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,130.00
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.37
(
-0.28%
)
Bitcoin
74,150.14
(
0.28%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 89942

Sunday, 01/31/2010 10:40:57 PM

Sunday, January 31, 2010 10:40:57 PM

Post# of 257253
You’re probably right that the “third” ABT drug is ABT-072; however, the only phase-2 trial relating to ABT-072 listed at clinicaltrials.gov is this one, which does not exactly sound promising vis-à-vis continued development:

http://clinicaltrials.gov/ct2/show/NCT00872196

Moreover, to my knowledge, ABT has not mentioned ABT-072 by name in any press release for almost a year (i.e. since #msg-35708745). That’s why I wasn’t sure.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today